Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
McKesson
US Department of Justice
Cerilliant
Johnson and Johnson
Fuji
Cipla
Farmers Insurance
Moodys

Generated: January 21, 2018

DrugPatentWatch Database Preview

Mesoridazine besylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for mesoridazine besylate and what is the scope of mesoridazine besylate freedom to operate?

Mesoridazine besylate
is the generic ingredient in one branded drug marketed by Novartis and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for mesoridazine besylate.
Medical Subject Heading (MeSH) Categories for mesoridazine besylate

US Patents and Regulatory Information for mesoridazine besylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SERENTIL mesoridazine besylate CONCENTRATE;ORAL 016997-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis SERENTIL mesoridazine besylate INJECTABLE;INJECTION 016775-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKesson
US Department of Justice
Farmers Insurance
Dow
Argus Health
McKinsey
Accenture
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot